Stanislaw Malicki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Stanislaw Malicki has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Barbara Chruscicka-Smaga
Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnologies, Jagiellonian University, Krakow, Poland
1 shared publication- Barbara Piątosa
Histocompatibility Laboratory, Children’s Memorial Health Institute, 04-730 Warsaw, Poland
1 shared publication - Danuta Bryzek
Microbiology Department, Faculty of Biochemistry Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland
1 shared publication - Dariusz Rokicki
Department of Pediatrics, Nutrition and Metabolic Diseases, Children’s Memorial Health Institute, 04-730 Warsaw, Poland
1 shared publication - Dorota Wesół-Kucharska
Department of Pediatrics, Nutrition and Metabolic Diseases, Children's Memorial Health Institute, Warsaw, Poland
1 shared publication Emilia Samborowska
Inborn Errors of Metabolism Laboratory, Children’s Memorial Health Institute, Warsaw, Poland
1 shared publication
Latest Publications
- Open Access
- 31 May 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (11) , 2790-2802
Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin
Neutropenia and neutrophil dysfunction in glycogen storage disease type 1b (GSD1b) are caused by the accumulation of 1,5-anhydroglucitol-6-phosphate in granulocytes. The antidiabetic drug empagliflozin reduces the concentration of 1,5-anhydroglucitol (1,5-AG), thus restoring neutrophil counts and functions, leading to promising results in previous case reports. Here, we present a comprehensive analysis of neutrophil function in 7 patients with GSD1b and 11 healthy donors, aiming to evaluate the immediate (after 3 months) and long-term (after 12 months) efficacy of empagliflozin compared with the reference treatment with granulocyte-colony stimulating factor (G-CSF). We found that most patients receiving G-CSF remained neutropenic with dysfunctional granulocytes, whereas treatment with empagliflozin increased neutrophil counts and improved functionality by inhibiting apoptosis, restoring phagocytosis and the chemotactic response, normalizing the oxidative burst, and stabilizing cellular and plasma levels of defensins and lactotransferrin. These improvements correlated with the decrease in serum 1,5-AG levels. However, neither G-CSF nor empagliflozin overcame deficiencies in the production of cathelicidin/LL-37 and neutrophil extracellular traps. Given the general improvement promoted by empagliflozin treatment, patients were less susceptible to severe infections. G-CSF injections were therefore discontinued in 6 patients (and the dose was reduced in the seventh) without adverse effects. Our systematic analysis, the most extensive reported thus far, has demonstrated the superior efficacy of empagliflozin compared with G-CSF, restoring the neutrophil population and normal immune functions. This trial was registered as EudraCT 2021-000580-78.
- 31 May 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (11) , 2790-2802
Open AccessNeutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin
Neutropenia and neutrophil dysfunction in glycogen storage disease type 1b (GSD1b) are caused by the accumulation of 1,5-anhydroglucitol-6-phosphate in granulocytes. The antidiabetic drug empagliflozin reduces the concentration of 1,5-anhydroglucitol (1,5-AG), thus restoring neutrophil counts and functions, leading to promising results in previous case reports. Here, we present a comprehensive analysis of neutrophil function in 7 patients with GSD1b and 11 healthy donors, aiming to evaluate the immediate (after 3 months) and long-term (after 12 months) efficacy of empagliflozin compared with the reference treatment with granulocyte-colony stimulating factor (G-CSF). We found that most patients receiving G-CSF remained neutropenic with dysfunctional granulocytes, whereas treatment with empagliflozin increased neutrophil counts and improved functionality by inhibiting apoptosis, restoring phagocytosis and the chemotactic response, normalizing the oxidative burst, and stabilizing cellular and plasma levels of defensins and lactotransferrin. These improvements correlated with the decrease in serum 1,5-AG levels. However, neither G-CSF nor empagliflozin overcame deficiencies in the production of cathelicidin/LL-37 and neutrophil extracellular traps. Given the general improvement promoted by empagliflozin treatment, patients were less susceptible to severe infections. G-CSF injections were therefore discontinued in 6 patients (and the dose was reduced in the seventh) without adverse effects. Our systematic analysis, the most extensive reported thus far, has demonstrated the superior efficacy of empagliflozin compared with G-CSF, restoring the neutrophil population and normal immune functions. This trial was registered as EudraCT 2021-000580-78.
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S755
Successful therapy of experimental, orthotopic renal cell carcinoma with two different types of Axl inhibiting agents
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S755
Successful therapy of experimental, orthotopic renal cell carcinoma with two different types of Axl inhibiting agents